413 related articles for article (PubMed ID: 35904579)
1. Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
Pedrazzi JFC; Ferreira FR; Silva-Amaral D; Lima DA; Hallak JEC; Zuardi AW; Del-Bel EA; Guimarães FS; Costa KCM; Campos AC; Crippa ACS; Crippa JAS
Psychopharmacology (Berl); 2022 Sep; 239(9):2713-2734. PubMed ID: 35904579
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol as a suggested candidate for treatment of autism spectrum disorder.
Poleg S; Golubchik P; Offen D; Weizman A
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Mar; 89():90-96. PubMed ID: 30171992
[TBL] [Abstract][Full Text] [Related]
3. Implications of the endocannabinoid system and the therapeutic action of cannabinoids in autism spectrum disorder: A literature review.
de Camargo RW; de Novais Júnior LR; da Silva LM; Meneguzzo V; Daros GC; da Silva MG; de Bitencourt RM
Pharmacol Biochem Behav; 2022 Nov; 221():173492. PubMed ID: 36379443
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of cannabidiol trials in neurodevelopmental disorders.
Parrella NF; Hill AT; Enticott PG; Barhoun P; Bower IS; Ford TC
Pharmacol Biochem Behav; 2023 Sep; 230():173607. PubMed ID: 37543051
[TBL] [Abstract][Full Text] [Related]
5. The role of cannabinoids in neurodevelopmental disorders of children and adolescents.
Dias-de Freitas F; Pimenta S; Soares S; Gonzaga D; Vaz-Matos I; Prior C
Rev Neurol; 2022 Oct; 75(7):189-197. PubMed ID: 36169325
[TBL] [Abstract][Full Text] [Related]
6. The Endocannabinoid System and Autism Spectrum Disorders: Insights from Animal Models.
Zamberletti E; Gabaglio M; Parolaro D
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28880200
[TBL] [Abstract][Full Text] [Related]
7. The effect of cannabidiol (CBD) on low-frequency activity and functional connectivity in the brain of adults with and without autism spectrum disorder (ASD).
Pretzsch CM; Voinescu B; Mendez MA; Wichers R; Ajram L; Ivin G; Heasman M; Williams S; Murphy DG; Daly E; McAlonan GM
J Psychopharmacol; 2019 Sep; 33(9):1141-1148. PubMed ID: 31237191
[TBL] [Abstract][Full Text] [Related]
8. Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.
Lamberti M; Siracusano R; Italiano D; Alosi N; Cucinotta F; Di Rosa G; Germanò E; Spina E; Gagliano A
Paediatr Drugs; 2016 Aug; 18(4):319-29. PubMed ID: 27278054
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.
Holdman R; Vigil D; Robinson K; Shah P; Contreras AE
Cannabis Cannabinoid Res; 2022 Aug; 7(4):451-463. PubMed ID: 34432543
[No Abstract] [Full Text] [Related]
10. Pharmacological inhibition of the primary endocannabinoid producing enzyme, DGL-α, induces autism spectrum disorder-like and co-morbid phenotypes in adult C57BL/J mice.
Fyke W; Alarcon JM; Velinov M; Chadman KK
Autism Res; 2021 Jul; 14(7):1375-1389. PubMed ID: 33886158
[TBL] [Abstract][Full Text] [Related]
11. Retracing our steps: A review on autism research in children, its limitation and impending pharmacological interventions.
Salloum-Asfar S; Zawia N; Abdulla SA
Pharmacol Ther; 2024 Jan; 253():108564. PubMed ID: 38008401
[TBL] [Abstract][Full Text] [Related]
12. Cannabinoid treatment for the symptoms of autism spectrum disorder.
Aran A; Cayam Rand D
Expert Opin Emerg Drugs; 2024 Mar; 29(1):65-79. PubMed ID: 38226593
[TBL] [Abstract][Full Text] [Related]
13. Autism Spectrum Disorder: A Review.
Hirota T; King BH
JAMA; 2023 Jan; 329(2):157-168. PubMed ID: 36625807
[TBL] [Abstract][Full Text] [Related]
14. Psychopharmacological interventions in autism spectrum disorder.
Accordino RE; Kidd C; Politte LC; Henry CA; McDougle CJ
Expert Opin Pharmacother; 2016; 17(7):937-52. PubMed ID: 26891879
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological management of behavioral disturbances in children and adolescents with autism spectrum disorders.
Lamy M; Erickson CA
Curr Probl Pediatr Adolesc Health Care; 2018 Oct; 48(10):250-264. PubMed ID: 30262163
[TBL] [Abstract][Full Text] [Related]
16. Brief Report: Cannabidiol-Rich Cannabis in Children with Autism Spectrum Disorder and Severe Behavioral Problems-A Retrospective Feasibility Study.
Aran A; Cassuto H; Lubotzky A; Wattad N; Hazan E
J Autism Dev Disord; 2019 Mar; 49(3):1284-1288. PubMed ID: 30382443
[TBL] [Abstract][Full Text] [Related]
17. Serotonin Receptors as Therapeutic Targets for Autism Spectrum Disorder Treatment.
Lee A; Choo H; Jeon B
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742963
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Anagnostou E
Curr Opin Neurol; 2018 Apr; 31(2):119-125. PubMed ID: 29389748
[TBL] [Abstract][Full Text] [Related]
19. Autism Spectrum Disorder: Classification, diagnosis and therapy.
Sharma SR; Gonda X; Tarazi FI
Pharmacol Ther; 2018 Oct; 190():91-104. PubMed ID: 29763648
[TBL] [Abstract][Full Text] [Related]
20. Cannabidiol and cannabis-inspired terpene blends have acute prosocial effects in the BTBR mouse model of autism spectrum disorder.
Staben J; Koch M; Reid K; Muckerheide J; Gilman L; McGuinness F; Kiesser S; Oswald IWH; Koby KA; Martin TJ; Kaplan JS
Front Neurosci; 2023; 17():1185737. PubMed ID: 37397463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
